Camozzi joins AMT on 18 July from Orphan Europe, where he held the position of medical director for more than five years. Prior to this, he was a strategic development manager in the Molecular Pathology department of Basel University Hospital, Switzerland. In this role, he interacted with both pharmaceutical customers and regulatory authorities.
From 2001–2005, Camozzi was md of MCP-medeor consulting pharma, where he helped design preclinical and clinical development programmes for pharmaceutical and healthcare products.
Dr Camozzi started his career in South America holding roles at Lederle/American Cyanamid and F Hoffmann La-Roche.
Amsterdam Molecular Therapeutics appoints chief medical officer
Dutch human gene therapy specialist hires Carlos Camozzi
You may also like
Research & Development
COVID-19 immunity lowers the risk of a new pandemic
Researchers at the MRC-University of Glasgow Centre for Virus Research have demonstrated that the likelihood of the emergence of a new SARS-type virus pandemic has been significantly reduced by population-wide immunity to SARS-CoV-2
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Cytiva enters research partnership with SRTIGET for next-gen genomic medicine
The pair aim to expand the role of lipid nanoparticle technology into gene therapy delivery, including applications in cancer and inherited blood diseases, CNS delivery for neurological disorders where current methods fail and in vivo stem cell modification that could eliminate toxic conditioning regimens